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1. Abstract 
Purpose: Multimorbid patients often take many different medicaments at the same 
time. Those can have clinically relevant interactions or can be overdosed, due to ne-
glected interactions or organ insufficiency. Especially in patients with renal insufficiency 
this can happen very easily. The aim of this study is to investigate whether multimorbid 
patients suffer from more medication errors than non-multimorbid patients.  
Methods: Anonymous patient data of 2014 from the University Hospital of Zurich were 
used to perform a retrospective data analysis. There are different kinds of medication 
interactions. First, there are drug-drug-interactions, which happen when two contraindi-
cated medicaments are falsely given together and can lead to an adverse drug reaction. 
Other interactions covered in this study are drug-disease interactions and dose adjust-
ment errors, where a drug has not been dose adjusted correctly in a patient with renal 
impairment. These interactions were identified for in the data and along their effects on 
patients’ mortality and morbidity. 
Results: We could show that the more diagnoses a patient has, the more likely it is that 
the patient has a medication error. The mortality of patients who had medication errors 
was 5.1% whereas the mortality of patients without medication error was at 2.3% (p<10-
12). It was also shown that patients with medication errors stayed longer in the hospital 
(15.6 days) versus the patients without medication errors (6.5 days) (p<10-15). 
Conclusions: Medication errors are a big problem in today’s hospitals. Due to in-
creased life expectancy multimorbidity is increasing and thus also medication lists are 
getting longer. In the environment of a hospital drugs are often falsely prescribed in a 
contraindicated combination or not dose adjusted for renal impairment. Those have a 
clinically relevant impact on the patient who is more likely to have an exaggerated 
course of disease leading to a higher mortality. The average length of hospital stay is 
also getting longer which implies that the medication interactions have an impact on 
patients’ morbidity and thus success of treatment.  
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2. List of abbreviations 
NSAID: Nonsteroidal anti-inflammatory drugs 
SSRI: Selective serotonin reuptake inhibitors 
ADR: Adverse Drug Reaction 
ACE-Inhibitors: Angiotensin-converting enzyme inhibitor 
ASS: Acetylsalicylic acid 
eGFR: estimated glomerular filtration rate 
NCS B-agents: Non-cardio selective beta agents 
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3. Introduction 
Today’s medicine enables people to get older than ever before. Before untreatable dis-
eases are now cured with a huge variety of interventions and medications – life expec-
tancy increases yearly (1). Advanced age and the associated illnesses cause that elder-
ly people have to take a large number of medications to treat those or keep them from 
progressing further (2). When taking different medications combined there is always a 
risk of having a side effect, an adverse drug reaction (ADR). ADR are injuries caused by 
taking a single drug or as a result of a combination of two or more drugs. They can 
manifest in a wide range of symptoms, ranging from a skin rash or a headache to se-
vere symptoms such as intracranial bleeding. ADR have the potential to increase mor-
tality and morbidity. (3) (4) 
Often there are contraindicated combinations of drugs. As the medication lists of multi-
morbid patients are getting longer, it is more likely that such maliciously interacting 
drugs are falsely given together (5). Another cause of adverse drug reactions are medi-
cations that should not be prescribed when a patient has a certain disease, for example 
non selective beta blockers and asthma (6). Such interactions were also examined in 
this study. 
Another important issue in adverse drug reactions is overdosing. Drug dosages are 
normally standardized for every medicament but sometimes have to be adjusted for pa-
tients with renal impairment. This can be overlooked easily and can lead to a higher 
concentration of the active component in the body of the patient because the kidney can 
not excrete these substances at a normal rate, leading to an accumulation of the sub-
stance, which then causes overdosing toxicity. (7) 
This study analyzes the effect of medication errors on the mortality and morbidity of the 
patients using the patient data of 2014 of the University Hospital of Zurich. Commonly 
falsely prescribed combinations of medication were searched for in the medication lists 
of the patients; therefore we retrospectively analyzed the effects of these interactions on 
the health of the patients. Using parameters such as the average length of hospital stay, 
it can be concluded what effect the medication errors have on the course of the disease 
and patient’s health. 
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4. Methods 
4.1. Study design 
The University Hospital Zurich yearly treats about 500’000 Patients in an out-patient 
setting and more than 38’000 patients as in-patients. The large number of patients with 
different diseases and treatments proves to be an optimal basis for a retrospective data 
analysis. This study is based on the patient data of 2014, in which every in-patient is 
registered in an anonymized database. This leads to a dataset including 38’793 patients 
and containing information about the patients age, sex, insurance and other demo-
graphic data, but also the diagnoses encoded by ICD-10. It also includes patients medi-
cation lists formalized as ATC codes. Furthermore all of the laboratory data that were 
acquired for a patient over the course of his hospital stay are also included into the da-
tabase.  
4.2. Data collection and variables studied  
To identify drug-drug interactions, drug-disease interactions and failed dose adjust-
ments, we first defined a reference list on what to search for in the data. It was looked 
for known medication interactions that are often prescribed together and are contraindi-
cated. Often prescribed medicaments such as NSAID are used to treat a variety of 
symptoms like pain, fever and inflammatory signs and can be falsely given to the patient 
without checking the patients’ medical history. A major concern was to find often pre-
scribed medications, as they are more likely to be combined with a contraindicated drug 
and also to find medications that are heavily contraindicated in combination because 
they could have severe effects on the patients’ health. As it was not the goal of the 
study to find all possible medication errors, table 1 shows the list of chosen interactions 
that are divided in the different interaction classifications. To get a good overview of the 
whole spectrum of adverse drug reactions, a variety of different medications were cho-
sen to get an overview in the different specialties in today’s medicine. 
 
 
 
 
 7 
Drug-disease interactions Drug-drug interactions Dose adjustment 
- Digoxin + potassium <2.8mM 
- potassium sparing diuretics + 
potassium >6mM 
- non cardio selective beta 
blockers + asthma 
- Metformin + eGFR <30 
- Metoclopramide + Parkinson’s 
- Thiazides (ex. Metolazone) + 
eGFR <30 
- NSAID + eGFR <30 
- Phenprocoumon + NSAID 
- Verapamil + Propanolol 
- loop diuretics + NSAID 
- NSAID + SSRI 
- SSRI + Triptane 
- ASS + Ibuprofen 
- ACE-Inhibitors + NSAID 
- Amiodarone + Haloperidol 
 
- Levetiracetam  
- Pregabalin 
- Rivaroxaban 
 
 
 
Morbidity and mortality are influenced by different factors including the patient’s actual 
health, his co-morbidities and the number of substances he has to take. To be able to 
show that the medication interactions have a significant effect on the patients outcome, 
patients health had to be quantified to make sure that it’s not just the higher number of 
diagnoses and substances that lead to an increase in mortality and morbidity. A coeffi-
cient was formed consisting of the duration of stay divided by the predicted duration of 
stay by DRG, which defines an optimal duration of stay with a certain disease. This 
helped to answer the question if the medication interactions had an effect on the dura-
tion of stay. A coefficient of 1 means that the patient’s hospital stay was as long as pre-
dicted, where as a coefficient of >1, it similes a longer stay than predicted and it could 
be assumed that the interactions had an effect on the patients outcome. 
4.3. Statistical analysis  
For the analysis of the patient data a python script (www.python.org) was used. It al-
lowed analyzing the vast amount of data for medication errors. Queries were pro-
grammed that searched in every patients medication list, whether drugs that are contra-
indicated were given within 24 hours using table 1 as reference. Also for laboratory data 
Table 1 Drug Interactions 
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such as eGFR or potassium there always had to be a maximal gap of 24 hours between 
the test result and the application of the next medicament to ensure that the patient was 
given the medicament when a contraindicating laboratory value was present in that 
moment.  
This resulted in a database quantifying the drug interactions for every patient. With this 
information, it was possible to identify how many interactions a patient had on average, 
how many diagnoses those patients with a high number of interactions had and how 
many different substances were taken in total. 
This table was imported and analyzed with R (www.r-project.org) and graphics such as 
boxplots and histograms to visually present the result were generated with this pro-
gramm. 
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5. Results 
5.1. Patient characteristics 
Based on the patient data of the University Hospital Zurich of the year 2014, 38’793 pa-
tients were analyzed for medication interactions listed in table 1. The examined patients 
consisted of 18’977 men (49%) and 19’816 women (51%) in which the mean age was 
49 ± 24 years (range: 1-104 years). On average every patient took 5.9 ± 4.9 substanc-
es (range: 1-51). The average length of hospital stay was 6.8 ± 9.7 days (range: 1-299 
days). The total number of individual doses of medication taken by a patient was on av-
erage 92.4 ± 201.3 (range: 1-6334). Of the 38'793 treated patients, 924 died (2.3%) in 
the course of their hospital stay. 
5.2. Outcome 
Patients with a high number of diseases had more medication errors than patients who 
had less than 10 diagnoses. As figure 1 shows, there is a correlation between the num-
ber of diagnoses and the number of drug interactions. 
  
 
Fig. 1 Patients with a high number of diagnoses are more likely to have medication errors. Boxplot showing 
the number of diagnoses relative tot he number of different interactions. Bar in the middle = median, box = 
25-75% Perzentile, Whiskers = 5-95% percentile. 
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Patients who had to take more medications had more medication errors than persons 
that only took a small amount of different medications, a correlation that is trivial and 
expected. Figure 2 shows the number of medications a patient received in the course of 
his hospital stay and the corresponding medication interaction. 
 
 
 
The mortality of patients without medication error was 2.3%. Those patients that had a 
minimum of one medication error had an average mortality of 5.1%. This is an increase 
in mortality of 2.8% (p<10-12).  
Patients without any medication error had an average hospital stay of 6.5 days where 
as patients with medication errors stayed in the hospital for 15.6 days (p<10-15). 
Figure 3 shows the different medication errors and their frequency excluding patients 
with no interactions. It shows that most medication errors of table 1 are loop diuretics 
combined with NSAID, NSAID given together with selective serotonin reuptake inhibi-
tors (SSRI) and angiotensin-converting-enzyme inhibitors (ACE-inhibitors) with NSAID. 
Fig. 2 Patients which have to take many substances over their course of hospital stay are more likely to 
have medication errors than patients with a lower drug-count. Boxplot showing the number of drug ap-
plications relative to the number of different interactions. Bar in the middle = median, box = 25-75% 
percentile, Whiskers = 5-95% percentile. 
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On the other side medication interactions concerning dose adjustment in patients with 
renal impairment did not occur often with the tested substances. 
 
 
It could be concluded that the more diagnoses a patient has and the more medications 
are taken to treat the diseases, the more likely it is that the higher mortality and morbidi-
ty are due to polypharmacy and diseases and not due to the number of drug-drug and 
drug-disease interactions. Table 2 and the ANOVA (analysis of variance) show a signifi-
cant effect on the morbidity and can still be observed even if corrected for the number of 
substances a patient takes. Moreover we developed a linear model, which shows a sig-
nificant increase of the duration of hospital stay by 0.005337 days (p<10-7) by every 
single medication interaction that occurs within a patient.  
Linear model:  
Duration of stay = 0.9 + number of substances * 0.00132 + 0.00534 * number of interac-
tions 
 
Fig. 3 Total count of individual interactions observed per patients shown relative to the different interac-
tions identified in the data set. Each single point depicts a patient with the quantified interactions; the 
vertical bar show the median of indidivual interactions per patient. The number at the right border 
shows the total count of every identified interaction.  
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  Degrees of freedom Sum of squares F statistic P - value 
Number of substances  1 6537 7716.58 <2e-16 
Number of interactions 1 17 20.13 7.26e-6 
Residuals 38752 32827   
 
Table 2 The ANOVA-Table shows that there is a significant influence of the medication errors on the 
morbidity of multimorbid patients 
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6. Discussion 
6.1. Key findings 
As shown in figure 1, patients with a higher number of diagnoses are more likely to have 
medication errors. With increasing number of diagnoses the number of occurring medi-
cation errors also rises, whereas patients with low a diagnose count seem to have less 
medication errors.  
Multimorbid patients with a large number of diagnoses are probably sicker and more 
likely to suffer from severe consequences than patients that present themselves with 
just a few diagnoses. So the mortality of those patients will normally be higher and as a 
consequence, they have to take more medications to cure these diseases. As figure 1 
shows, it is more likely to have medication interactions when patients have a high num-
ber of diagnoses. Multimorbid patients with many diseases also have a higher mortality 
rate, so it is not clear what role medication errors play in the mortality rate of multimor-
bid patients. As the ANOVA in table 2 shows, medication errors have a significant influ-
ence on the mortality of the patients, even if corrected for the number of substances.  
Medication errors also have an effect on the morbidity patients. Morbidity can be meas-
ured with different parameters, a simple surrogate is the duration of the hospital stay. 
Patients without any medication errors have an average length of hospital stay of 6.5 
days whereas patients with one or more medication errors stay in the hospital for 15.6 
days on average (p<10-15). It also has an effect on the mortality of the patients. Persons 
without medication errors have a mortality of 2.8% where as patients with more than 
one medication error have a mortality rate of 5.1% (p<10-12). This means that there are 
patients who die because of medication errors when they otherwise could have sur-
vived.  
Most medication errors happened when non-steroidal anti-inflammatory drugs (NSAID) 
were involved. They are often prescribed because of their analgesic and anti-
inflammatory effects. They can be used to alleviate pain or against inflammation and 
fever. Known contraindications for NSAIDs are gastric and duodenal ulcers and known 
liver and kidney diseases. As NSAIDs are so commonly used for a wide range of treat-
ments it is not a surprise that they are commonly falsely prescribed. 
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Also an influence of the number of substances taken and the number of medication in-
teractions on the duration of hospital stay was found. We showed that every single in-
teraction increases the duration of hospital stay by 0.005337 days (p<10-7). This 
demonstrates clearly that medication interactions raise the morbidity rate even when 
subtracting the effects of the basal disease and the number of substances taken. 
We could not show an influence of the medication interactions on mortality when cor-
rected for age and number of substances. Probably this is due to the low overall mortali-
ty rate of 2%. 
6.2. Comparison to other studies 
Verbeeck et al (7) did a study about dose adjustment in patients with renal dysfunction 
and came to the same conclusion, that adverse drug reactions are common in patients 
with renal insufficiency. Also Calderón-Larrañaga et al (8) came to the result that multi-
morbidity leads to an accumulation of adverse drug reaction. Other studies such as the 
study from Buckley et al (9) used a different approach for the detection of medication 
errors by direct observation of the physicians. This leads to a higher personal effort and 
an investigator-biased detection system compared to the objective measures of this 
study because the observers could only see the errors the physicians made and could 
not specifically search for drugs or diseases that seemed interesting to them. In sum-
mon, all of those studies come to the conclusion that adverse drug reactions are a prob-
lem in todays’ hospital treatment and it should be searched for solutions because those 
errors can have a significant effect on patients’ health. 
6.3. Strengths and limitations of the study 
The study clearly shows an impact of medication errors on patients’ health and their 
mortality. With the high number of patients included in this study, it can give a repre-
sentative survey on the effects of these errors. The study does not depend on active 
surveillance of physicians prescribing medicaments or on patients’ subjective side ef-
fects. It thus can monitor physicians’ treatments objectively and in a very large number.  
The fact that there is plethora of data provided for each patient makes a solid foundation 
for more analyses on even more medication interactions with the same approach.  
A limiting factor in the significance of the study is that the University Hospital of Zurich is 
a tertiary hospital and as that, is treating patients that are normally sicker than patients 
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in a community hospital. So this study with its data represents only the University Hospi-
tal of Zurich and the mortality and the number of medication errors can differ from com-
munity hospitals. However, a generalization to tertiary hospitals is probably sound, since 
the effect is clear and the differences in populations small. 
It was shown, that the more diagnoses a patient has, the more likely it is that a medica-
tion error is present as more drugs to treat the diseases have to be taken. A problem of 
this study is, that it does not include patient’s actual health. When a patient is already 
severely ill, a medication error could make a bigger difference in the outcome compared 
to a patient who is young and relatively fit.  
When a patient is in great need of a medicament but has a contraindication like high 
blood potassium or when a medicament that is contraindicated is taken, physicians 
have to decide whether there is a better solution that prevents a possible medication 
error, or if they hazard the consequences of the medication interaction. Since this will 
not show up in our data, a probably false assumption that it was falsely given to the pa-
tient is made in this case. 
This study only can observe what was documented. Whether or not the right medication 
had been given has not and can not be studied by our method. Mistakes often happen 
when medical personal distributes the medicaments, since no data concerning such 
errors was available to us, further studies are necessary to cover these questions. 
6.4. Significance of the study 
The results of this study show that medication errors are a problem in today’s hospital 
care. As we just tested a small list of medication interactions, more could be found, if 
someone looked for even more medication interactions.  
Today hospitals, in times of diagnosis-related groups (DRG), tend to keep the patients 
length of hospital stay at a minimum to reduce costs and to have space for another pa-
tient that generates income. Longer hospital stays mean more costs for the hospital. As 
medication errors extend the hospital stay on average about 9 days, it should thus be in 
a hospitals interest to keep these medication errors to a minimum out of a solely eco-
nomic point of view. 
Ultimately it is also most important to check every patients medication list for errors be-
cause it can have a severe effect on the outcome on his disease. It would be desirable 
that drug interaction checkers such as for instance www.drugs.com or others would be 
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considered more often to check the medication lists of patients, because they can give 
information about the drug-drug-interactions and drug-disease-interactions of a patient. 
This could keep the medication errors at a minimum. However, at our hospital such a 
system has been present at the time of the study, so awareness for medication errors 
has to be improved also. 
 
6.5. Unanswered Questions 
To check the influence of the medication errors an interventional study would have to be 
conducted, which actively reduces the drug-drug- and drug-disease-interactions to find 
out if the benefit on morbidity and mortality suggested by this study persists also in a 
prospective study. 
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